Aug 8 |
Barinthus Biotherapeutics GAAP EPS of -$0.43 misses by $0.03
|
Aug 8 |
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
|
Aug 1 |
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
|
Jun 6 |
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
|
May 13 |
Barinthus Biotherapeutics GAAP EPS of -$0.40
|
May 13 |
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
|
May 4 |
Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
|
May 1 |
Barinthus Biotherapeutics names Hooftman as chief medical officer
|
May 1 |
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
|
Apr 18 |
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
|